Editor's Note: At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Georg Lenz from the University of Münster, Germany, on behalf of the FRONTMIND study group, delivered an oral presentation on the final analysis results of the Phase 3 FRONTMIND study. This study aimed to investigate the efficacy and safety of adding the CD19 monoclonal antibody Tafasitamab and the immunomodulatory drug Lenalidomide to the standard R-CHOP regimen (hereafter referred to as Tafa-Len+R-CHOP) for the frontline treatment of patients with high-risk diffuse large B-cell lymphoma (DLBCL). 01 Research Background: Unmet Needs in Frontline Treatment of High-Risk DLBCL
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of adult lymphoma, accounting for approximately 40% of cases. Although the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen has been the standard of care for many years, approximately 40% of high-risk patients still face treatment failure or relapse. For high-risk populations defined by an International Prognostic Index (IPI) score of 3-5 or an age-adjusted IPI (aaIPI) score of 2-3, long-term survival benefits still need to be improved. Tafasitamab is an Fc-engineered monoclonal antibody targeting CD19. The previous L-MIND study confirmed its significant activity in combination with lenalidomide in relapsed/refractory (R/R) DLBCL. Based on this, the FRONTMIND study further explored the clinical potential of the Tafa-Len+R-CHOP regimen in previously untreated high-risk patients.
02 Study Design: A Global, Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial
FRONTMIND is a global, double-blind, randomized, Phase 3 clinical trial (NCT04824092). • Study Population: Patients with previously untreated DLBCL meeting the high-risk definition (IPI 3-5 or aaIPI 2-3). To ensure alignment with real-world clinical needs, the study required the interval between diagnosis and the initiation of therapy to be ≤28 days. • Grouping Regimen: Patients were randomized 1:1 to either the experimental arm (Tafa-Len+R-CHOP for 6 cycles) or the control arm (R-CHOP for 6 cycles). • Primary Endpoint: Investigator-assessed progression-free survival (PFS). • Secondary Endpoints: Event-free survival (EFS), overall survival (OS), and safety. A total of 1,229 patients were screened, and 899 eventually entered the randomization phase, with 448 in the experimental arm and 451 in the control arm. Baseline characteristics were balanced between the two groups: more than 80% of patients had elevated lactate dehydrogenase (LDH), and more than 40% had an aaIPI score of 3, fully reflecting the high-risk nature of the enrolled population.
03 Primary Efficacy Analysis: Significant Improvements in PFS and EFS
Results from a median follow-up of 35.9 months showed that the primary endpoint, PFS, was significantly improved. • PFS Data: Compared with the standard R-CHOP regimen, the Tafa-Len+R-CHOP regimen reduced the risk of disease progression, relapse, or death by 25% (HR=0.75). • 2-Year PFS Rate: 71.1% (95% CI: 66.7-75.1%) in the experimental arm versus 62.9% (95% CI: 58.2-67.2%) in the control arm, with an absolute benefit (Delta) of 8.2%. • EFS Benefit: Regarding the secondary endpoint EFS, the experimental arm also demonstrated significant superiority. • OS Analysis (Interim): The 2-year OS rate showed a beneficial trend (84.1% vs 80.5%, a difference of 3.6%). Median OS has not yet been reached, and further follow-up is required to confirm the survival benefit.
04 Evaluation of Deep Remission: MRD Negativity Rate and Subgroup Analysis
To further investigate the depth of remission, minimal residual disease (MRD) monitoring was performed using capture-based ctDNA detection technology (conducted by Professor Christiane Pott’s team in Kiel, Germany). • MRD Negativity Rate: At the end of treatment, the MRD negativity rate in the experimental arm was 81.3%, significantly higher than the 66.7% in the control arm. This result suggests that the Tafa-Len combination regimen can induce deeper and more thorough molecular remission. • Subgroup Benefit: Subgroup analysis based on Germinal Center B-cell-like (GCB) and Activated B-cell-like (ABC) subtypes showed that the Tafa-Len+R-CHOP group exhibited consistent PFS advantages regardless of the Cell of Origin (COO) classification. Particularly in ABC-type patients, who were previously considered to have a worse prognosis, the combination regimen also showed significant benefits.
05 Safety Characteristics: Increased Hematological Toxicity but Generally Manageable
In terms of safety, the toxicity profile of the Tafa-Len+R-CHOP regimen was consistent with the known adverse events (AEs) of each individual drug. • Common AEs: The proportion of Grade 3 or higher treatment-emergent adverse events (TEAEs) was higher in the experimental arm than in the control arm. The primary increase was due to hematological toxicities, including neutropenia, anemia, and thrombocytopenia, which also led to a slightly higher incidence of neutropenic fever. • Non-hematological Toxicity: Gastrointestinal toxicities were more common in the experimental arm, but most were low-grade and clinically manageable. • Special Context: The study was conducted during the peak of the COVID-19 pandemic (2021-2023). The number of deaths due to COVID-19 and related lung infections was slightly higher in the experimental arm than in the control arm. • Intensity of the Backbone Regimen: Key data indicated that the addition of Tafa and Len did not compromise the relative dose intensity (RDI) of the R-CHOP regimen. Except for vincristine, the median RDI for all other components in both groups was nearly 100%.
06 Conclusion and Clinical Significance: A New Landscape for Frontline Treatment of High-Risk DLBCL
In his summary, Professor Georg Lenz emphasized that the FRONTMIND study confirms that adding Tafasitamab and lenalidomide to R-CHOP provides a significant and clinically meaningful PFS benefit for patients with high-risk DLBCL. Although Polatuzumab Vedotin (Pola) combined with R-CHP (POLARIX study) has become the current standard regimen for some previously untreated DLBCL patients, the FRONTMIND study provides another effective “R-CHOP+” option for clinical practice. Professor Lenz pointed out that while the POLARIX study showed benefits primarily in the IPI 2-5 population, the FRONTMIND study focused more on the higher-risk subgroups, and the improvement in its MRD negativity rate holds high academic value. In the future, how to accurately select Tafa-Len+R-CHOP or other combination regimens based on molecular typing and risk assessment will be an important research direction for individualized frontline treatment of DLBCL.
Expert Profile:
Professor Georg Lenz
Director of the Department of Hematology and Oncology at the University Hospital Münster, Germany. He has long been dedicated to the molecular pathogenesis of malignant lymphoma, the development of novel targeted drugs, and clinical translational research, holding profound academic influence in the field of both previously untreated and relapsed/refractory DLBCL. Academic Keywords: Diffuse Large B-cell Lymphoma (DLBCL); Tafasitamab; Lenalidomide; R-CHOP; FRONTMIND Study; Progression-Free Survival (PFS); Minimal Residual Disease (MRD).
